If you are attending and want to discuss trends and best practices related to market access, innovative contracting, or patient support services, please reach out. We'd love to connect.
read full article ›Health is important today and every day, but too many do not have access or can’t afford it.
read full article ›Market access and drug pricing are top topics for potential legislation in Congress right now.
read full article ›Tomorrow is #NationalDoctorsDay and, boy, is our debt high right now. If ever there was a moment to say thank you, this is it.
read full article ›Rob O'Brien just returned from the Employers Health Pharmacy Benefit Conference, where biosimilars, state and federal regulations and paying for cell and gene therapies were all top of mind. Read on to hear what stuck with him.
read full article ›An interesting article from The Pink Sheet caught our eye. It analyzes the EUA for molnupiravir, Merck’s COVID-19 pill, which gained emergency use partly for its accessibility.
read full article ›Real Endpoints views the Prescription Digital Therapeutics Act of 2022 as a critical piece of legislation to help broaden appropriate access to prescription digital therapeutics (PDTs), an emerging therapeutic modality.
read full article ›On IWD22 day, we are excited to announce that Real Endpoints’ Susan Raiola will be moderating an all women panel at BIO featuring industry experts discussing patient-centered value based arrangements.
read full article ›Its déjà vu all over again…much like psoriasis, atopic derm is an increasingly crowded category where new entrants may hold some clinical differentiation, but in the ways that matter to payers, they all look exactly the same.
read full article ›For Rare Disease Day, please join Real Endpoints in raising awareness of individuals living with rare disease.
read full article ›